Atossa
Atossa Subsidiary NRLBH, BioVentive Ink Marketing Deal
NEW YORK (GenomeWeb) – Atossa Genetics announced today that its subsidiary, the National Reference Laboratory for Breast Health, and BioVentive have reached a deal to market and promote NRLBH's services.
Atossa Genetics announced the hiring of Jelle Kylstra as its new VP of clinical research and development. Kylstra joined the company on May 19, and brings with her more than 23 years of industry experience.
Atossa's 2013 Revenues Rise 31 Percent
NEW YORK (GenomeWeb News) – Atossa Genetics said after the close of the market on Thursday that its full-year 2013 revenues grew 31 percent year over year on increased product sales.
Atossa Prices Public Offering, Expects $14M in Gross Proceeds
NEW YORK (GenomeWeb News) – Atossa Genetics today priced its public offering of 5.8 million units at $2.40 per unit, saying it anticipates raising $14 million in gross proceeds.
Atossa Files for FDA Clearance of Recalled Breast Cancer Test
NEW YORK (GenomeWeb News) – Atossa Genetics said on Tuesday that it has submitted a premarket 510(k) notification with the US Food and Drug Administration for its ForeCYTE breast cancer test device.
Nov 13, 2013
Atossa Q3 Revenues Fall 27 Percent
Aug 15, 2013
Atossa's Q2 Revenues Rise 46 Percent
Jul 8, 2013
Jun 17, 2013
Atossa Signs on Third PPO for Breast Cancer Test
Jun 7, 2013
Mar 13, 2013
Atossa Inks Deal with PPO for Breast Cancer Tests
Feb 25, 2013
Atossa Warned by FDA Over its MASCT Platform
Dec 20, 2012
Atossa Genetics Pulls In $106K in Q3 Revenues
Nov 8, 2012